Hematopoietic stem cell defects are thought to be involved in the etiopathogenesis of systemic autoimmune disease. Positively selected, stem cell-enriched populations of wheat germ agglutinin-positive (WGA+) low-density bone marrow and fetal liver cells from normal and autoimmune-prone mice were used to determine whether reciprocal transplantation of stem cells between normal and autoimmune-prone mice inhibits or causes development of autoimmune disease. NZB recipients of DBA/2 stem cell populations analyzed >100 days after bone marrow or fetal liver cell transplantation showed decreased levels of anti-DNA antibodies and decreased glomerular lesions when compared with nontreated NZB mice or NZB recipients of NZB stem cell preparations. Female DBA/2 recipients of WGA+ NZB bone marrow cell or fetal liver cell transplants exhibited elevated serum autoantibody levels and developed glomerular lesions characteristic of NZB mice when analyzed >100 days after transplantation. These pathological disturbances were not observed in DBA/2 recipients ofDBA/2 stem cell preparations. The data indicate that WGA+ stem cells from autoimmune-prone NZB mice contain the genetic defects responsible for the development of systemic autoimmune disease.
row and fetal liver cells from normal and autoimmune-prone mice were used to determine whether reciprocal transplantation of stem cells between normal and autoimmune-prone mice inhibits or causes development of autoimmune disease. NZB recipients of DBA/2 stem cell populations analyzed >100 days after bone marrow or fetal liver cell transplantation showed decreased levels of anti-DNA antibodies and decreased glomerular lesions when compared with nontreated NZB mice or NZB recipients of NZB stem cell preparations. Female DBA/2 recipients of WGA+ NZB bone marrow cell or fetal liver cell transplants exhibited elevated serum autoantibody levels and developed glomerular lesions characteristic of NZB mice when analyzed >100 days after transplantation. These pathological disturbances were not observed in DBA/2 recipients ofDBA/2 stem cell preparations. The data indicate that WGA+ stem cells from autoimmune-prone NZB mice contain the genetic defects responsible for the development of systemic autoimmune disease. Several investigators recently have described the separation of murine hematopoietic stem cells from among the cells present in hematopoietic tissues such as bone marrow and fetal liver (1) (2) (3) (4) (5) . The availability of cell preparations greatly enriched with hematopoietic stem cells has facilitated study of the role of stem cells in immunological and hematological disease. Using established cell-transfer technique, we examined whether the development of systemic autoimmune disease in NZB mice could be prevented by using a combination of lethal total-body irradiation (TBI) and i.v. transplantation of positively selected stem cell-enriched preparations ofbone marrow cells (BMC) or fetal liver cells (FLC) from normal DBA/2 mice. We also examined whether stem cell preparations from NZB mice transplanted into DBA/2 mice could induce autoimmune disease.
Recent approaches to stem cell separation and identification have included separations based on density (1) (2) (3) (4) 6) , antigen or antigen-receptor expression (5, (7) (8) (9) (10) , or lectinreceptor expression (1, 2, (11) (12) (13) . Using a combination of negative selection to deplete mature cell populations followed by positive selection of labeled stem cells, we (13) and others (5) separated stem cells more completely than was possible by using negative or positive selection alone. Positive-selection techniques have involved labeling stem cells with lectins--e.g., soybean agglutinin (12) These results provide additional strong evidence to implicate stem cell defects in the development of systemic autoimmune disease in mice. Female DBA/2 mice (8-10 weeks old) were exposed to 9.5-10 Gy of TBI and then administered i.v. stem cell preparations from either BMC of adult NZB mice or pooled liver cells from fetal (gestation days [17] [18] [19] [20] CFU-S Assay. CFU-S were quantitated as described (13) . Briefly, 4-24 hr before cell transfer, mice were irradiated with 7.5-8.0 Gy and injected i.v. with appropriate concentrations of cells. Recipient mice were sacrificed 8 and 12 days after transplant, and their spleens were removed and fixed in Bouin's solution. Visible surface colonies were counted. Irradiated mice that did not receive cell preparations had fewer than one colony per spleen (data not shown).
MATERIALS AND METHODS
Evaluation of Serum Anti-DNA Autoantibodies. Autoantibody titers in serum samples from mice that received transplants were evaluated as described (27) . Serum was collected from blood drawn from the retro-orbital plexus just before sacrifice, placed in microaliquot vials (Eppendorf), and separated from clotted blood by centrifugation at 16,000 x g for 20 min in a micro-centrifuge (Eppendorf, 5415). Aliquots (50 pl) of the separated serum were stored at -20'C until use.
Calf thymus DNA (no. 2618, lot 704275; Calbiochem) was dissolved (20 ,ug/ml) in 0.5 M carbonate buffer (pH 9.6). One hundred microliters of DNA solution was added to each well of an Immulon 2, 96-well microtiter plate (Dynatech) and then incubated for 1 hr at 370C followed by three washes with phosphate-buffered saline containing 0.05% Tween 20 (pH 7.4) (washing buffer). Coated plates were stored in the dark at 40C for up to 2 weeks prior to use. Fifty microliters of serum diluted 1:100 in washing buffer was added to each well and incubated for 1 hr at room temperature (RT). Plates were washed three times with washing buffer, and 50 Al of a 1:350 dilution of alkaline phosphatase-conjugated goat anti-mouse Ig (Sigma) was added to each well. The plates were incubated for 1 hr at RT and then washed three times with washing buffer. Fifty microliters of disodium p-nitrophenylphosphate (Sigma) at 1 mg/ml was added to each well, and the plate was incubated 15-40 min at RT in the dark. Plates were read at 410 nm with a Minireader 650 (Dynatech); optical densities were recorded and analyzed with an Apple IIC and Immunosoft software (Dynatech). Values were standardized by using a sample of pooled serum from 7-month-old male NZB mice that was included in each plate of every experiment.
Histological Analysis. Histological sections (2 ,um) of the kidneys of transplanted mice and controls were prepared from formalin-fixed tissues and stained with periodic acid/ Schiff reagent or hematoxylin and eosin stain (28) . The glomeruli were evaluated for membrane thickening and other morphological changes and scored from 0 to 4+ (0, no detectable pathology; 4+, gross membrane thickening indicative of advanced glomerular damage). A minimum of 100 glomeruli from each mouse were scored blindly by two pathologists using coded samples.
Statistical Analysis. Unless otherwise stated, statistical significance was determined by analysis of variance (ANOVA, Scheffe's post hoc test) and Student's t test. P values < 0.05 were considered significant.
RESULTS
Separation of Low-Density WGAI Cells Enriched for Hematopoietic Activity. Murine BMC and FLC that contained hematopoietic progenitors were separated from nonhematopoietic progenitors and tested for ability to form mixed lineage CFU-S as described. Flow cytometric analyses from (Fig. 2) . In addition, glomerular lesions characteristic of NZB mice (Fig. 3 Upper Left) that were not observed in untreated DBA/2 mice (Fig.  3 Lower Left) or DBA/2 recipients of DBA/2 cells (not shown) developed in the DBA/2 mice administered unseparated NZB cells (Fig. 3 Upper Right) or low-density WGA' cells ( Fig. 3 Lower Left).
Prevention of Systemic Autoimmunity in NZB Recipients of DBA/2 Stem Cell Preparations. To determine whether marrow or stem cell replacement in autoimmune-prone mice prevents the genetically programmed development of systemic autoimmunity, young adult NZB mice were subjected tCell donor -* recipient. to TBI and infused either with unseparated BMC or FLC or with preparations of stem cell-enriched fractions as described. The NZB mice that received either Fr-2 cells or Fr-2 WGA+ FLC or BMC as well as recipients of unseparated hematopoietic cells were examined 105-152 days after transplantation for evidence of autoimmune disease. NZB recipients of low-density WGA+ cells from either DBA/2 bone marrow or fetal liver had significantly decreased levels of anti-DNA autoantibody levels in serum (Fig. 4) . Similarly, histological examination of renal tissue from NZB recipients of DBA/2 whole bone marrow, Fr-2 cells or low-density WGA' stem cell preparations revealed the absence of the glomerular basement membrane thickening characteristic of untreated NZB mice. The glomeruli of the transplanted NZB mice (Fig. 5 Bottom) appeared normal in comparison with the strikingly abnormal glomeruli of untreated NZB mice (Fig. 5 Top) or NZB recipients of NZB low-density WGA+ BMC (data not shown).
DISCUSSION
Considerable experimental evidence suggests that the etiopathogenesis of systemic and organ-specific autoimmune disease originates from defects present in hematopoietic stem cells (20, 23, (29) (30) (31) (32) . Results of several studies conducted in our laboratories (23, 33, 34) and by others (19-22, 24, 25) indicate that replacement of stem cells using bone marrow transplantation (BMT) can dramatically modulate development of autoimmune disease. Indeed, we have shown that BMT can be used to treat systemic autoimmune disease in autoimmune-prone mice (23, 33, 34) . Although these studies provided evidence that BMT may be a viable treatment for systemic autoimmune disease, because of the difficulty of isolating stem cell-enriched preparations, conclusive data implicating stem cell defects in the etiology and pathogenesis of systemic autoimmune disease was only recently obtained.
Transplantation of stem cell-enriched fractions can transfer systemic, cell-specific, and organ-specific autoimmune disease from autoimmune-prone to autoimmune-resistant mice (6) trated based on either the presence of stem cell antigens (5) or receptors for lectins (1, 2) . We previously obtained stem cell-enriched fractions from murine (4, 13) and monkey (17) bone marrow by positively selecting low-density BMC that bind WGA.
In the present analyses we found that low-density WGA' cells as well as low-density or unseparated cells obtained from normal DBA/2 bone marrow or fetal liver and then transplanted into irradiated young NZB mice greatly decreased the levels of serum anti-DNA autoantibodies and prevented almost completely the development of glomerular lesions in recipient NZB mice. Conversely, transfer of lowdensity WGA' cells from NZB mice to lethally irradiated normal DBA/2 mice resulted in development of elevated levels of serum anti-DNA autoantibodies and NZB-like glomerular lesions in the DBA/2 mice. In other studies we observed that the low-density WGA' cells contain progenitors for immunologically competent lymphocytes (18) . Some NZB mice treated with up to 11 Gy of TBI and then infused with DBA/2 WGA+ BMC or FLC possessed similar numbers of donor-derived as well as recipient-derived lymphocytes in the spleen (18) . However, in the thymuses of these mice, by far the vast majority of lymphocytes were of donor origin. These findings suggest that despite the persistence of a significant proportion of NZB-derived lymphocytes in spleens of recipient mice, the disease process was nevertheless offset by stem cell transplantation, even when analyzed more than 150 days later. Thus, cells derived from the marrow of autoimmune-resistant mice may be able to inhibit expression of systemic autoimmune disease-a subject worthy of further investigation.
The importance of the recipient-derived cells in the spleen remains to be determined. However, it has been observed that in MRL/lpr mice, the correction of autoimmune disease by using lethal TBI followed by BMT is transient and that manifestations of disease are prone to recur in these animals (34) . The recurrence of disease in MRL/lpr mice is correlated with the reappearance of MRL/lpr-derived lymphocytes (34) . Therefore, it appears that either significant improvements in myeloablative therapy or additional restorative manipulations to promote the persistence of the disease-correcting allogenic stem cells must be achieved to cure or prevent autoimmunity or lymphoproliferative disease that occurs in the MRL/lpr mice. Recently described methods that combine myeloablative drugs with TBI should now be examined to determine whether these methods are more effective in eliminating radioresistant progenitors from autoimmune-prone mice (35) . Further studies are needed to probe the molecular and genetic nature of the stem cell defect responsible for the development of autoimmunity and to ascertain, if the abnormal genes are identified, whether expression of the homologous genes from the autoimmune-resistant mice or the genes of the mice with autoimmune potential can be introduced appropriately to either cause or cure the autoimmune disorder.
